These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29858161)

  • 1. Difficult choices in treating Parkinson's disease psychosis.
    The Lancet Neurology
    Lancet Neurol; 2018 Jul; 17(7):569. PubMed ID: 29858161
    [No Abstract]   [Full Text] [Related]  

  • 2. Pimavanserin for Parkinson Disease Psychosis.
    Mohanty D; Sarai S; Naik S; Lippmann S
    Prim Care Companion CNS Disord; 2019 Apr; 21(2):. PubMed ID: 31050230
    [No Abstract]   [Full Text] [Related]  

  • 3. Pimavanserin as treatment for Parkinson's disease psychosis.
    Fox SH
    Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566
    [No Abstract]   [Full Text] [Related]  

  • 4. Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
    Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096
    [No Abstract]   [Full Text] [Related]  

  • 5. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
    Stahl SM
    CNS Spectr; 2016 Oct; 21(5):355-359. PubMed ID: 27686027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
    Moreno GM; Gandhi R; Lessig SL; Wright B; Litvan I; Nahab FB
    Neurology; 2018 Oct; 91(17):797-799. PubMed ID: 30258020
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.
    Kingwell K
    Nat Rev Neurol; 2013 Dec; 9(12):658. PubMed ID: 24247322
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological interventions for psychosis in Parkinson's disease patients.
    Friedman JH
    Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
    Kyle K; Bronstein JM
    Parkinsonism Relat Disord; 2020 Jun; 75():55-62. PubMed ID: 32480308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
    Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW
    Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Psychosis in Parkinson's disease and sudden death.
    Kyle K; Bronstein JM
    Parkinsonism Relat Disord; 2020 Oct; 79():127. PubMed ID: 32943345
    [No Abstract]   [Full Text] [Related]  

  • 16. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.